Sort   by:  
 Page size 

Nonalcoholic steatohepatitis (NASH) prevalence is rising with no pharmacotherapy approved. A major hurdle in NASH drug development is the poor translatability of preclinical studies to safe/effective clinical outcomes, and recent failures highlight a need to identify new targetable pathways. Dysr...

2023-04-13 | MTBLS5005 | MetaboLights

In recent years, nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease globally. Studies indicate that the gut-liver axis plays an important role in the occurrence and development of this disease. Our previous studies showed that the gut microbiota and gut meta...

2025-07-02 | MTBLS12668 | MetaboLights

The aim of this study was to investigate the hepatoprotection of Schisandra chinensis Caulis polysaccharides (SCP) in the nonalcoholic fatty liver disease (NAFLD) induced by high-fat diet (HFD) in rats. A total of 30 Wistar rats were randomly divided into control group (CON), model group...

2021-08-24 | MTBLS3194 | MetaboLights
Background Nonalcoholic steatohepatitis (NASH) represents a growing global health challenge due to its propensity to progress to irreversible hepatic disorders, including fibrosis, cirrhosis, and carcinoma. This study aimed to investigate the role of gut microbiota in the pathogenesis of NASH. We ha...
2025-06-23 | MTBLS12631 | MetaboLights
Non-alcoholic fatty liver disease (NAFLD) is a consequence of sedentary life style and high fat diets with an estimated prevalence of about 30% in western countries. It is associated with insulin resistance, obesity, glucose intolerance and drug toxicity. Additionally, polymorphisms in, e.g. APOC3, ...
2015-12-07 | MTBLS174 | MetaboLights
Not available
ORGANISM(S): Homo sapiens 
Nonalcoholic fatty liver disease represents a spectrum of pathology that ranges from benign steatosis to potentially-progressive steatohepatitis and affects more than 30% of US adults. Advanced NAFLD is associated with increased morbidity and mortality from cirrhosis, primary liver cancer, cardiovas...
ORGANISM(S): Homo sapiens 
Nonalcoholic fatty liver disease (NAFLD) including its more severe manifestation, nonalcoholic steatohepatitis (NASH), is a global public health challenge. Here, we reveal a role for the deubiquitinating enzyme RPN11 in the development of NAFLD and NASH. Ablation of hepatic RPN11 markedly protected ...
ORGANISM(S): Homo Sapiens Mus Musculus 
2024-06-15 | PXD053163 |
We analyzed the transcriptome for drug metabolism genes of 35 human (17 healthy control (HC), and 18 nonalcoholic fatty liver disease (NAFLD)) liver tissues, obtained during laparoscopic cholecystectomy. The aim of our study is to identify the drug metabolism genes significantly regulated by NAFLD a...
ORGANISM(S): Homo sapiens 
Sort   by:  
 Page size